Introduction
Patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) are a high-risk group for adverse clinical outcomes. Increased inflammatory status pre-PCI and directly post-PCI has been associated with poor prognosis. 1, 2 Residual inflammatory risk (RIR) has gained much interest since the publication of the CANTOS trial (The Canakinumab Anti-inflammatory Thrombosis Outcomes Study) and describes the inflammatory status in patients with known cardiovascular disease. The definition used for high RIR was a high sensitive C-reactive protein (hsCRP) levels >2 mg/L and low-density lipoprotein (LDL) cholesterol >70 mg/dL. 3, 4 Routine clinical practice includes assessment of residual cholesterol and thrombotic risk in patients with cardiovascular disease, as recommended by the European Society of Cardiology (ESC) Guidelines. 5, 6 The importance of lowering these risks in patients after PCI has been well established. [5] [6] [7] [8] However, the prevalence of persistent high RIR in PCI-patients is not well established and assessment of RIR is not recommended in current guidelines. Moreover, clinical outcomes associated with different patterns of RIR are unknown in patients after PCI. We aim to determine the prevalence of persistent high RIR in patients undergoing PCI, and to evaluate the association with adverse clinical outcomes at 1 year after PCI.
Methods

Study design and population
Data from a prospective PCI registry of a large-volume PCI centre (Mount Sinai Hospital, NY, USA) was used for this retrospective analysis. This registry includes information on patient-, procedure-related, and follow-up data, extracted from the electronic health records. An institutional review board approved the registry.
All patients undergoing PCI between 1 January 2009 and 31 December 2016 with > _2 serial hsCRP measurements with > _4 weeks between both measurements were included in this analysis. Patients with no hsCRP levels or only one blood sample with hsCRP level determination post-PCI were excluded from the analysis.
Patients were stratified into four groups according to RIR. High inflammatory status was defined as hsCRP >2 mg/L. Patients with two high values were considered as persistent high RIR. Patients with first high, then low hsCRP were considered as attenuated RIR and patients with first low-then high hsCRP were considered as increased RIR. Patients with consistent low hsCRP were labelled persistent low RIR (Take home figure) .
Clinical endpoints
The primary endpoint of this analysis was 1 year all-cause death. Time-to-event was measured from first hsCRP measurement. Secondary endpoints were myocardial infarction (MI, using third universal definition 9 ), target vessel revascularization, target lesion revascularization, bleeding, stent thrombosis, cerebrovascular accident (CVA), major adverse cardiovascular events (MACE), and MACEþ. MACE was defined as the composite of all-cause death, MI, and stroke. The composite endpoint of all-cause death, MI, stroke, and any revascularization was defined as MACEþ. All events were adjudicated by a clinical event committee.
Statistical analysis
Categorical data are presented as numbers and percentages and compared using the v 2 test. Continuous data are presented as means ± standard deviations and compared using the independent-samples t-test. Clinical outcomes were analysed using the Kaplan-Meier method and compared using the log-rank test. Sensitivity analysis was done according to acute coronary syndrome (ACS) presentation, sex, and baseline LDL cholesterol (< _70 mg/dL or >70 mg/dL). Multivariable
Take home figure Concept of residual inflammatory risk and the main findings of this study. High high sensitive C-reactive protein is defined as >2 mg/L. a Adjusted for age, gender, body mass index, acute coronary syndrome, diabetes mellitus, hypertension, chronic kidney disease, previous coronary artery bypass graft, and baseline low-density lipoprotein cholesterol. Red hazard ratio indicates a P-value <0.01. MACE, major adverse cardiovascular events, composite of death, MI, and CVA; MACEþ, MACE with any revascularization; MI, myocardial infarction.
analysis was performed using Cox regression including age, gender, body mass index (BMI), ACS, diabetes mellitus (DM), hypertension, chronic kidney disease (CKD), history of coronary artery bypass graft (CABG), and baseline LDL. A fully adjusted model was performed using all baseline variables with a statistical significant difference between the four RIR groups. The primary endpoint death and the secondary endpoints were tested for the proportional hazard assumption before assessing the final Cox Models. This was tested by including a time dependent covariate in a Cox Model. An interaction term between the exposure of interest (inflammatory risk) and a function of survival time was then generated. If the time dependent covariate was significant, then the exposure was not proportional. P-values <0.05 were considered statistically significant.
Results
Patient cohort
The patient flowchart is presented in Figure 1 . Patients with no hsCRP at baseline (N = 716) and patients with only one hsCRP measurement or when time between measurements was <4 weeks (N = 15.037) were excluded, resulting in 7.026 
Baseline characteristics according to residual inflammatory risk
Mean age in the total cohort was 64.42 ± 11.06 years. The percentage of female patients was significantly higher in patients with persistent high RIR (37.2% vs. 20 .2% in persistent low, 26 .2% in attenuated RIR, and 27.4 in increased RIR), P < 0.01. Patents with persistent high RIR had a higher prevalence of DM and CKD, and were more frequently current smokers. Acute coronary syndrome was more frequent in patients with persistent high RIR and patients with attenuated RIR. Table 2 shows the baseline characteristics.
Clinical outcomes according to residual inflammatory risk
The primary endpoint was observed in 2.6% of persistent high, 1.0% of increased RIR, 0.3% of attenuated RIR, and 0.7% of persistent low RIR, P-value <0.01 ( Figure 2A) . Myocardial infarction occurred in respectively 7.5%, 6 .40%, 4.6%, and 4.3% of patients, P < 0.01 ( Figure 2B ). MACE was seen in 9.7% of persistent high RIR, 6 .9% increased RIR, 5.1% in both attenuated, and persistent low RIR (P < 0.01), MACEþ was as follows 26.1%, 22.5%, 24 .2% and 21.4%, P < 0.01 ( Figure 2C and D). No statistical differences were found between groups for 1 year bleeding, stent thrombosis, or CVA. All clinical outcomes are presented in Table 3 . Table 4 shows the unadjusted and adjusted hazard ratio (HR) for the four different RIR groups. When adjusted for age, gender, BMI, ACS, DM, hypertension, CKD, previous CABG, and baseline LDL, we find that the persistent high RIR has a HR of 3.2 for 1 year allcause death (reference is persistent low), and a HR of 1.6 for 1 year MI (Take home figure) . Supplementary material online, Appendix S2 shows the fully adjusted model, where all 34 baseline variables were included in which statistically significant imbalance was present at baseline. The findings remained unchanged in this full adjusted model.
PCI Registry
Fully adjusted model and sensitivity analyses
Supplementary material online, Appendix S2 shows the fully adjusted model, where all 34 baseline variables were included in which statistically significant imbalance was present at baseline. The findings remained unchanged in this full adjusted model.
Sensitivity analysis according to ACS is presented in Supplementary material online, Appendix S3. Outcomes were consistent between both groups, although the difference between RIR and MI was not statistically significant in non-ACS patients.
Supplementary material online, Appendix S4 presents the sensitivity analysis according to sex. Due to a higher percentage of female patients in the persistent high RIR group this subgroup was a specific focus. In both sexes the association is present, but overall stronger in male patients.
We performed an analysis according to LDL cholesterol (Supplementary material online, Appendix S5) where we found the same association, and an even stronger association in patients with LDL cholesterol <70 mg/d.
Discussion
The main findings of this analysis are: (i) serial hsCRP values are identified in a third of patients undergoing PCI, (ii) persistent high RIR is observed frequently in these patients and is associated with higher 1 year all-cause death and MI, and (iii) The association between persistent high RIR and mortality or MI is present in ACS-patients and stable patients, male and female and normal and high LDL cholesterol and remain sustained after adjustment.
Prevalence of persistent high residual inflammatory risk
We report presence of RIR in patients based on serial hsCRP measurements. In over a third of PCI-patients serial hsCRP was available and a high percentage of persistent high RIR (38%) was observed. In patients in whom no serial hsCRP was available, hsCRP at baseline was higher. Even using the most conservative assumption; i.e. that these patients have low serial hsCRP, the total percentage of patients with persistent high RIR still accounts for 11.7% of the total PCI population (N = 2.654 out of 22.779 patients). This is the first analysis, to our knowledge, that reports the prevalence of persistent high RIR after PCI.
Prevalence of residual inflammatory risk in patients with atherosclerosis and on statin therapy in the PROVE-IT trial 10 was 43%, 47% in the IMPROVE-IT trial, 11 and 61% in the VIRGO registry. 12, 13 The prevalence found in our registry is in line, though slightly lower. However, over 95% of patients in this dataset have arterial hypertension and hyperlipidaemia. Many drugs used in these diseases also have anti-inflammatory action and may change the hsCRP assay. 
Inflammatory status and clinical outcomes at 1 year follow-up
Stratifying PCI-patients to RIR based on serial hsCRP could predict clinical outcomes in this analysis. The Take home figure depicts the concept of RIR and our main findings. Numerous publications report single assessment of (hs-)CRP and cardiovascular events in patients without a history of cardiovascular disease. [14] [15] [16] In patients with acute myocardial infarction (AMI) or coronary stenting, robust evidence for association of single pre-procedural CRP and clinical outcomes was found. [17] [18] [19] One study evaluating single hsCRP at 30-day post-AMI found no association. 21 Pre-procedural CRP has proven to be prognostic in elective PCI. 1, 22, 23 We investigated serial hsCRP. Moreover, we included only those at least 4 weeks between measurements to account for temporary high hsCRP in ACS or other potential transient causes of increased hsCRP such as current infection. 24, 25 These results support our finding from this analysis in patients after PCI.
Persistent high residual inflammatory risk in specific subgroups
We analysed three specific subgroups: patients with baseline LDL cholesterol <70 mg/dL, women, and ACS. We found the prognostic factor of persistent high RIR was sustained in elective patients. Because of a relatively higher number of female patients in patients with persistent high RIR, we performed a sensitivity analysis according 
Clinical implications
Reducing inflammatory risk by anti-inflammatory medication has recently been shown to be feasible and effective. The CANTOS trial showed that the interleukin-1b antibody Canakinumab reduced recurrent cardiovascular events compared with placebo in patients with previous MI and increased baseline hsCRP (>2 mg/L), independent of lipid-level lowering. 3 Moreover, the magnitude of the CRP reduction was associated directly with the magnitude of clinical benefit. 26 The ongoing randomized CIRT trial (NCT01594333) investigates the use of low-dose methotrexate or placebo to reduce major cardiovascular events in patients with Type 2 diabetes or metabolic syndrome and prior MI or known multivessel disease. 27 Our analysis shows that determining RIR in PCI-patients identifies a high-risk population. Whether the use of anti-inflammatory medication in this population reduces recurrent cardiovascular events deserves further investigation.
Limitations
Some limitations should be taken into account when interpreting the data in this study. This is a retrospective analysis of a prospective registry, therefore, hsCRP measurements were not performed in a 
Conclusion
A high percentage of patients undergoing PCI have persistent high RIR, which results in a higher 1 year rate of death and MI. This inflammatory risk profile should be investigated and treatment options in this high-risk patient population should further be explored.
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